Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
89bio Inc. (ETNB) Insider Trading Activity
Healthcare • Biotechnology • 70 employees
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Total Value
$49,673,009.11
Total Shares
6,674,742
Average Trade Value
$1,602,355.13
Most Active Insider
Ra Capital Management, L.P.
Total Activity: $49,999,994
Largest Single Transaction
$49,999,994
by Ra Capital Management, L.P. on Jan 30, 2025
30-Day Activity
4 Transactions
Volume: 6,129 shares
Value: $64,784
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Medical Officer
|
Feb 17, 2025 | 1,050 | $11,099 | 318,834 (-0.3%) | Payment of Exercise Price | |
|
Chief Executive Officer
|
Feb 17, 2025 | 3,249 | $34,342 | 862,240 (-0.4%) | Payment of Exercise Price | |
|
See Remarks
|
Feb 17, 2025 | 1,050 | $11,099 | 343,652 (-0.3%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Feb 17, 2025 | 780 | $8,245 | 269,674 (-0.3%) | Payment of Exercise Price | |
|
Chief Medical Officer
|
Feb 9, 2025 | 3,817 | $43,552 | 319,884 (-1.2%) | Payment of Exercise Price | |
|
See Remarks
|
Feb 9, 2025 | 3,793 | $43,278 | 344,702 (-1.1%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Feb 9, 2025 | 3,828 | $43,677 | 270,454 (-1.4%) | Payment of Exercise Price | |
|
Chief Executive Officer
|
Feb 9, 2025 | 8,946 | $102,074 | 864,692 (-1.0%) | Payment of Exercise Price | |
|
Chief Medical Officer
|
Feb 1, 2025 | 80,000 | $10,000 | 327,039 (+24.5%) | Grant | |
|
Chief Medical Officer
|
Feb 1, 2025 | 3,338 | $32,045 | 323,701 (-1.0%) | Payment of Exercise Price | |
|
Chief Operating Officer
|
Feb 1, 2025 | 53,750 | $10,000 | 78,750 (+68.3%) | Grant | |
|
Chief Financial Officer
|
Feb 1, 2025 | 3,338 | $32,045 | 274,282 (-1.2%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Feb 1, 2025 | 80,000 | $10,000 | 277,620 (+28.8%) | Grant | |
|
Chief Executive Officer
|
Feb 1, 2025 | 200,000 | $10,000 | 883,236 (+22.6%) | Grant | |
|
Chief Executive Officer
|
Feb 1, 2025 | 212,000 | $10,000 | 683,236 (+31.0%) | Grant | |
|
Chief Executive Officer
|
Feb 1, 2025 | 9,598 | $92,141 | 873,638 (-1.1%) | Payment of Exercise Price | |
|
See Remarks
|
Feb 1, 2025 | 80,000 | $10,000 | 351,833 (+22.7%) | Grant | |
|
See Remarks
|
Feb 1, 2025 | 3,338 | $32,045 | 348,495 (-1.0%) | Payment of Exercise Price | |
|
See Remarks
|
Feb 1, 2025 | 8,750 | $84,000 | 14,750 (+59.3%) | Grant | |
| Jan 30, 2025 | 5,714,285 | $49,999,994 | 19,554,319 (+29.2%) | Purchase | ||
| Jan 22, 2025 | 10,000 | $67,100 | 25,000 (+40.0%) | Purchase | ||
| Jan 21, 2025 | 5,000 | $32,750 | 15,000 (+33.3%) | Purchase | ||
|
See Remarks
|
Jan 15, 2025 | 10,963 | $71,150 | 271,833 (-4.0%) | Sale | |
|
Chief Medical Officer
|
Dec 12, 2024 | 95,000 | $0 | 247,039 (+38.5%) | Grant | |
|
See Remarks
|
Dec 12, 2024 | 6,000 | $10,000 | 6,000 (+100.0%) | Grant | |
|
Chief Financial Officer
|
Dec 12, 2024 | 95,000 | $0 | 197,620 (+48.1%) | Grant | |
|
See Remarks
|
Dec 12, 2024 | 95,000 | $0 | 282,796 (+33.6%) | Grant | |
|
Chief Executive Officer
|
Dec 6, 2024 | 5,000 | $39,450 | 471,236 (+1.1%) | Purchase | |
| Dec 5, 2024 | 10,000 | $80,000 | 10,000 (+100.0%) | Purchase | ||
|
Chief Executive Officer
|
Nov 22, 2024 | 10,000 | $83,500 | 466,236 (+2.1%) | Purchase | |
|
See Remarks
|
Oct 30, 2024 | 27,955 | $226,995 | 187,796 (-14.9%) | Sale |